ʻO Rimegepant kahi mea hoʻokae mole liʻiliʻi o kacalcitoningene-related peptide (CGRP) receptor e ālai ana i ka hana a CGRP, he vasodilator potent i manaʻoʻiʻo e pāʻani i ke ʻano o ka migraine headache. Ua ʻae ʻia ʻo Rimegepant no ka mālama ʻana i nā hōʻeha o ka migraine. I loko o nā hoʻokolohua lapaʻau, ua ʻae maikaʻi ʻia ka rimegepant me nā manawa kakaikahi wale nō o ka piʻi ʻana o ka serum aminotransferase transient i ka wā o ka lāʻau lapaʻau a me ka hōʻike ʻole ʻia o nā hōʻeha o ka ate.

ʻO Rimegepant kahi mea kū'ē waha o ka mea hoʻokipa CGRP i hoʻomohala ʻia e Biohaven Pharmaceuticals. Ua loaʻa iā ia ka FDA i ka lā 27 Pepeluali, 2020 no ka mālama ʻana i ka maʻi ʻeha o ka migraine. ʻOiai ua ʻae ʻia kekahi mau mea kūʻē makua o CGRP a me kāna mea loaʻa no ka migraine therapy (eg [erenumab], [fremanezumab], [galcanezumab]), rimegepant a me [ubrogepant] ʻo ia wale nō nā lālā o ka ʻohana "gepants" o nā lāʻau lapaʻau i koe i ka hoʻomohala ʻana, a ʻo nā mea kūʻē CGRP wale nō i loaʻa ka bioavailability waha. ʻO ka maʻamau o kēia manawa o ka migraine therapy e pili ana i ka hoʻomaʻamaʻa abortive me "triptans", e like me [sumatriptan]. Ua lilo ka antagonism o ke ala CGRP i mea hoʻokipa maikaʻi no ka migraine therapy no ka mea, ʻaʻole like me nā triptans, ʻaʻole i ʻike nā antagonists waha CGRP i nā waiwai vasoconstrictive a no laila ʻoi aku ka palekana no ka hoʻohana ʻana i nā maʻi me nā contraindications i ka lāʻau maʻamau.

ʻO Rimegepant kahiCalcitoninʻO Antagonist Peptide Receptor pili i nā Gene. ʻO ke ʻano hana o ka rimegepant e like me aCalcitoninʻO Antagonist Peptide Receptor pili i nā Gene.